GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Aerovate Therapeutics
The stock of Aerovate, a biotech company developing a drug to treat pulmonary arterial hypertension, reflects the potential of its core product. The price chart is a classic biotech story, with the value determined by expectations of clinical trial results.
Share prices of companies in the market segment - Heart
Aerovate Therapeutics is a biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension. We've categorized it as a "Heart" company. The chart below shows how investors value companies offering new approaches to treating rare diseases.
Broad Market Index - GURU.Markets
Aerovate Therapeutics is a biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension. A component of the GURU.Markets index, it offers new approaches to treating rare diseases. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
AVTE - Daily change in the company's share price Aerovate Therapeutics
For Aerovate Therapeutics, Inc., which develops drugs for pulmonary hypertension, daily price changes are a measure of enormous volatility. This metric reflects extreme sensitivity to clinical trial data and is key to risk assessment.
Daily change in the price of a set of shares in a market segment - Heart
Aerovate Therapeutics is a biopharmaceutical company developing a drug for the treatment of pulmonary arterial hypertension. Cardiology is a risky area of research. The chart below illustrates the high volatility typical of the biotech sector, reflecting the stakes associated with AVTE's development.
Daily change in the price of a broad market stock, index - GURU.Markets
Aerovate Therapeutics is a biotech company specializing in the treatment of cardiovascular diseases. Given the prevalence of these diseases, its developments are attracting attention. Its shares are volatile and dependent on research progress, contributing to market dynamics.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Aerovate Therapeutics
For Aerovate Therapeutics, the year-over-year trend is a story about the development of its inhaled drug for the treatment of pulmonary arterial hypertension. Its 12-month market cap depends entirely on clinical trial data. The success of its innovative approach could fundamentally change the standard of treatment for this serious disease.
Annual dynamics of market capitalization of the market segment - Heart
Aerovate, as an early-stage biotech, is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its heart disease drugs. Its stock price will reflect the speculative faith of investors.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Aerovate Therapeutics, a biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension, is a one-product company. Its annual market capitalization growth is entirely dependent on the success of this drug in clinical trials.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Aerovate Therapeutics
Aerovate is a clinical-stage biopharmaceutical company. Its monthly performance is entirely dependent on the results of its clinical trials. Data on its inhaled drug for the treatment of pulmonary hypertension is a key event for investors.
Monthly dynamics of market capitalization of the market segment - Heart
Aerovate Therapeutics is focused on developing an inhaled drug for the treatment of pulmonary arterial hypertension, a serious heart and lung disease. The chart below shows how investors viewed the prospects for new, more patient-friendly treatments in this complex therapeutic area.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Aerovate Therapeutics is a biotech company focused on treating rare cardiovascular diseases. Its stock price will be determined entirely by the results of clinical trials. This is a high-risk bet on success in a very narrow and complex field of medicine.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Aerovate Therapeutics
Shares of Aerovate Therapeutics, a clinical-stage biopharmaceutical company, are extremely volatile. Weekly price movements depend entirely on news about the progress of clinical trials for their drug for the treatment of pulmonary arterial hypertension. The chart below illustrates how short-term scientific events can cause sharp price fluctuations.
Weekly dynamics of market capitalization of the market segment - Heart
Aerovate Therapeutics is developing an inhaled drug for the treatment of pulmonary arterial hypertension. This could radically change the lives of patients. The chart below shows how expectations for this breakthrough product are creating its own highly volatile trend for the company's stock.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Aerovate Therapeutics is a biopharmaceutical company. This chart shows how its weekly performance, like that of other biotechs, is detached from the market. Share price movements are driven by clinical trial news and regulatory decisions, not macroeconomic data.
Market capitalization of the company, segment and market as a whole
AVTE - Market capitalization of the company Aerovate Therapeutics
The valuation of Aerovate Therapeutics (AVTE) on the chart is a concentrated bet on its inhaled drug for the treatment of pulmonary arterial hypertension. This clinical-stage biotech's market cap is entirely dependent on the success of this single asset's trials. The dynamics clearly illustrate the binary outcome: breakthrough or failure.
AVTE - Share of the company's market capitalization Aerovate Therapeutics within the market segment - Heart
Aerovate Therapeutics's stake in cardiology is focused on the treatment of pulmonary arterial hypertension. Its market share is based almost entirely on the potential of its inhaled drug, which could become a breakthrough and convenient treatment for patients with this serious condition.
Market capitalization of the market segment - Heart
The chart illustrates the total value of biotech companies focused on cardiovascular disease treatment. Aerovate Therapeutics is one such player. The dynamics on the chart reflect the high volatility and risks associated with clinical trials in this complex field.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart visualizes hope for patients with pulmonary hypertension. Aerovate Therapeutics' (ticker symbol AVTE) market cap reflects investors' faith in its innovative inhalation drug. The line shows how the biotechnology company is generating enormous potential value in global medicine.
Book value capitalization of the company, segment and market as a whole
AVTE - Book value capitalization of the company Aerovate Therapeutics
Aerovate Therapeutics, a clinical-stage company, derives its book value from its scientific potential. The chart below reflects the financial valuation of its intellectual property for an inhaled drug for the treatment of pulmonary arterial hypertension. The dynamics demonstrate how the company is investing in the development of its core asset.
AVTE - Share of the company's book capitalization Aerovate Therapeutics within the market segment - Heart
Aerovate Therapeutics' tangible assets include its R&D infrastructure for developing an inhaled formulation of a drug for the treatment of pulmonary arterial hypertension. The chart shows its share of this scientific base, which is the foundation for its innovative approach.
Market segment balance sheet capitalization - Heart
Biotechnology is a world of contrasts. The graph shows the enormous factories of pharmaceutical giants. Aerovate Therapeutics, as a development company, has a more streamlined model. Its value lies in its intellectual property, not in the scale of production that is typical of the R&D stage.
Book value of all companies included in the broad market index - GURU.Markets
Aerovate Therapeutics is developing an inhaled drug for the treatment of pulmonary arterial hypertension. The company's assets are not factories, but intellectual property and clinical trial data. The chart shows the material resources devoted to combating this serious disease.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Aerovate Therapeutics
Aerovate Therapeutics is a biotech company developing a drug for the treatment of pulmonary arterial hypertension. Its asset is intellectual property. The chart below is a pure indicator of faith in science. Its dynamics will depend entirely on the results of clinical trials.
Market to book capitalization ratio in a market segment - Heart
Aerovate Therapeutics, Inc. is a biotech company developing an inhaled drug for the treatment of pulmonary arterial hypertension. Its value depends on the success of its lead product. This chart shows how its market valuation is a bet on the future and is significantly disconnected from its current assets.
Market to book capitalization ratio for the market as a whole
Aerovate Therapeutics is a biopharmaceutical company developing a drug for the treatment of pulmonary arterial hypertension. The market valuation shown in this chart is based on the high potential of their lead candidate. The dynamics reflect expectations for key clinical trials.
Debts of the company, segment and market as a whole
AVTE - Company debts Aerovate Therapeutics
Aerovate Therapeutics, a clinical-stage biotech, is using raised capital to develop its inhaled drug for the treatment of pulmonary arterial hypertension. This chart shows how the company is spending funds on expensive trials in its quest to bring a more convenient treatment to market.
Market segment debts - Heart
Aerovate Therapeutics is a clinical-stage biotech developing an inhaled drug for the treatment of pulmonary arterial hypertension. This chart shows how its debt policy (or lack thereof) reflects the need to finance expensive clinical trials with equity capital to bring this potentially breakthrough product to market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Aerovate Therapeutics
Aspira Women's Health develops diagnostic tests for women's health, specifically for ovarian cancer detection. This chart shows how the company funds its research, development, and commercialization of its products. Success in medical diagnostics requires significant and long-term investment.
Market segment debt to market segment book capitalization - Heart
Aerovate Therapeutics is a clinical-stage biotech developing an inhaled drug for the treatment of pulmonary arterial hypertension. This chart compares its debt load to the overall market capitalization of the pharmaceutical sector. It shows how the company is funding its key clinical trials.
Debt to book value of all companies in the market
Aerovate Therapeutics is a clinical-stage biopharmaceutical company developing a treatment for pulmonary arterial hypertension, a serious condition with an unmet medical need. This chart of total market debt shows the environment in which the company is raising capital for its key clinical trials.
P/E of the company, segment and market as a whole
P/E - Aerovate Therapeutics
For Aerovate Therapeutics, a biotech company, the P/E ratio is not applicable. It has no profit, and its valuation on this chart is arbitrary. It is a speculative bet that its drug for treating pulmonary hypertension will prove safe and effective in clinical trials.
P/E of the market segment - Heart
Aerovate Therapeutics is a biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension, a rare and serious condition. Their goal is to offer a more convenient and effective treatment. This chart shows the average valuation for the cardiology sector, reflecting investor hopes for a breakthrough in the treatment of this serious condition.
P/E of the market as a whole
Aerovate Therapeutics — see JBIO. The company is focused on developing an inhaled drug for the treatment of pulmonary arterial hypertension, a promising area in cardiology. This chart, reflecting risk appetite, provides insight into how investors view biotech companies working on serious diseases.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Aerovate Therapeutics
Aerovate Therapeutics is a biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension. This chart reflects market expectations for the success of this more convenient form of therapy. Future revenue depends on the results of clinical trials.
%20P%2FE%20Aerovate%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Aerovate-Therapeutics&v=1772648087161 "Chart of the company's future (projected) P/E Aerovate Therapeutics")
Future (projected) P/E of the market segment - Heart
Aerovate Therapeutics is a clinical-stage biopharmaceutical company developing a drug for the treatment of pulmonary arterial hypertension. This chart is a measure of investor expectations. It shows how the market views the potential of its lead candidate compared to other drugs in this field.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Heart&v=1772648087205 "Future (projected) P/E graph of the market segment - Heart")
Future (projected) P/E of the market as a whole
Aerovate Therapeutics is a clinical-stage biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension. Its future depends entirely on the success of clinical trials. This chart, reflecting market optimism, demonstrates the investor appetite for risk required to finance such long-term projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772648087349 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Aerovate Therapeutics
Aerovate Therapeutics is a clinical-stage biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension. Its financial performance is driven by R&D expenditures. This chart illustrates the significant investments required to develop a potentially breakthrough and patient-friendly treatment.
Profit of companies in the market segment - Heart
Aerovate Therapeutics is a biopharmaceutical company focused on developing treatments for rare heart and lung diseases. This graph, showing overall profitability in the sector, highlights the potential of niche markets. Aerovate's success in developing a new drug could not only generate huge profits but also transform the lives of patients.
Overall market profit
Aerovate Therapeutics is a biotech company developing an inhaled drug for the treatment of pulmonary arterial hypertension. This inhaled formulation may offer significant advantages over existing treatments.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Aerovate Therapeutics
Aerovate Therapeutics is a biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension. Future revenue projections are speculative and depend on the success of clinical trials.
%20profit%20of%20the%20company%20Aerovate%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Aerovate-Therapeutics&v=1772648087568 "Graph of future (projected) profit of the company Aerovate Therapeutics")
Future (predicted) profit of companies in the market segment - Heart
Aerovate Therapeutics is a biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension. This chart shows overall profitability forecasts for the cardiology and pulmonology sector. It helps understand how a patient-friendly drug formulation could change the market and how this compares to overall expectations.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Heart&v=1772648087629 "Graph of future (predicted) profits of companies in a market segment - Heart")
Future (predicted) profit of the market as a whole
Aerovate Therapeutics is a clinical-stage biopharmaceutical company focused on treating lung diseases. Its success depends on trial results. This chart, reflecting investor sentiment, is important for Aerovate. During periods of market optimism, companies in its sector more easily attract the capital needed to continue expensive development.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772648087686 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Aerovate Therapeutics
Aerovate Therapeutics is a clinical-stage biopharmaceutical company developing a drug for the treatment of pulmonary arterial hypertension. This chart, plotting its market capitalization against its missing revenue, reflects the valuation of its key asset. It demonstrates investors' belief that its inhaled drug will be a breakthrough in the treatment of this disease.
P/S market segment - Heart
Aerovate Therapeutics is a biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension (PAH). The company aims to offer a more convenient and effective treatment option. This chart reflects investor estimates of biotech revenue, reflecting expectations for the clinical results and commercial potential of Aerovate.
P/S of the market as a whole
Aerovate Therapeutics is a biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension. This chart, which displays the average valuation, shows that investors value the company based on the potential of its lead product candidate.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Aerovate Therapeutics
Aerovate Therapeutics is a clinical-stage biopharmaceutical company developing a drug for the treatment of pulmonary arterial hypertension. This chart shows the market's estimate of its potential future revenue, reflecting investor confidence in the commercial potential of its inhaled drug.
%20P%2FS%20Aerovate%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Aerovate-Therapeutics&v=1772648087841 "The graph of the company's future (projected) P/S Aerovate Therapeutics")
Future (projected) P/S of the market segment - Heart
Aerovate Therapeutics is a clinical-stage biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension. The chart shows the average estimated future sales in the cardiology sector. It helps understand how investors view the potential of this new treatment approach and the associated clinical risks.
%20P%2FS%20market%20segment%20graph%20-%20Heart&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Heart&v=1772648087864 "Future (projected) P/S market segment graph - Heart")
Future (projected) P/S of the market as a whole
Aerovate Therapeutics (AVTE) is a clinical-stage biotech developing an inhaled drug for the treatment of pulmonary arterial hypertension. Their future depends solely on the results of clinical trials. This market sentiment chart has no bearing on their mission.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772648088046 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Aerovate Therapeutics
Aerovate Therapeutics is a clinical-stage biotech company focused on the treatment of pulmonary arterial hypertension. It has no sales revenue. It is developing an inhaled drug that could change the treatment approach. The graph will reflect future revenue from licensing or partnerships following successful trials.
Sales of companies in the market segment - Heart
Aerovate Therapeutics is a clinical-stage biopharmaceutical company focused on developing an inhaled drug for the treatment of pulmonary arterial hypertension. It currently has no sales revenue. Its future revenue depends on the success of this innovative drug delivery method.
Overall market sales
Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a drug for the treatment of pulmonary arterial hypertension. Its value is determined by its scientific prospects. The overall economic situation, reflected in this chart, influences the availability of capital for the biotech sector, which is necessary for conducting lengthy and expensive trials.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Aerovate Therapeutics
Aerovate Therapeutics is a biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension. Future revenue is dependent on the success of clinical trials. This graph reflects long-term development expectations.
%20sales%20of%20the%20company%20Aerovate%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Aerovate-Therapeutics&v=1772648088404 "Schedule of future (projected) sales of the company Aerovate Therapeutics")
Future (projected) sales of companies in the market segment - Heart
Aerovate Therapeutics is developing an inhaled drug for the treatment of pulmonary arterial hypertension, a serious heart and lung disease. This chart shows revenue projections for the entire cardiology sector. It reflects the urgent need for new, more convenient, and effective treatments, creating significant market potential for Aerovate's innovative approach.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Heart&v=1772648088478 "Schedule of future (projected) sales of companies in the market segment - Heart")
Future (projected) sales of the market as a whole
Investment activity in the pharmaceutical industry, closely linked to the forecasts in this chart, determines the prospects of Aerovate Therapeutics. The biotech company is developing drugs for the treatment of pulmonary arterial hypertension. Funding for its research depends on capital inflows into the sector.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772648088523 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Aerovate Therapeutics
Aerovate Therapeutics is a clinical-stage biotechnology company developing an inhaled drug for the treatment of pulmonary arterial hypertension. This graph reflects its investment in research. Future profitability depends on the success of clinical trials and the ability to offer a convenient and effective therapy.
Market segment marginality - Heart
Aerovate Therapeutics is a biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension. Profitability depends on the success of this development in clinical trials. This chart shows the average profitability in the pharmaceutical industry. It helps assess how much its innovative approach can change the treatment of this serious condition.
Market marginality as a whole
Aerovate Therapeutics is a biopharmaceutical company developing drugs to treat rare heart and lung diseases. Being in the clinical stage, its survival depends on its ability to attract capital. This chart reflects the overall investment climate and risk appetite. It shows whether investors are willing to fund long-term, capital-intensive research and development.
Employees in the company, segment and market as a whole
Number of employees in the company Aerovate Therapeutics
Aerovate Therapeutics is a clinical-stage biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension. This graph shows a compact team focused on R&D. Growth will mean progress in clinical trials, which will require expansion of the team to prepare for potential market entry.
Share of the company's employees Aerovate Therapeutics within the market segment - Heart
Aerovate Therapeutics is focused on developing AV-101, an innovative inhaled drug for the treatment of pulmonary arterial hypertension, a rare and severe heart and lung disease. This chart shows the percentage of all specialists in this highly specialized field that the company attracts. This is a direct indicator of the concentration of scientific talent needed to bring a breakthrough drug to market.
Number of employees in the market segment - Heart
Aerovate Therapeutics is a biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension. This chart, showing employment in the cardiology and pulmonology research sector, is important. The growing number of scientists in this field indicates a high need for more convenient and effective treatments for this rare disease.
Number of employees in the market as a whole
Aerovate Therapeutics is a biotechnology company specializing in the treatment of pulmonary arterial hypertension. This overall employment chart reflects the economic foundation that allows funding for the development of drugs for rare diseases. Only in a stable and growing economy is the investment necessary to bring such drugs to market possible.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Aerovate Therapeutics (AVTE)
Aerovate Therapeutics (AVTE) is a biopharmaceutical company developing an inhaled drug for the treatment of pulmonary arterial hypertension. This is a classic R&D business. Its entire market value is a bet investors have made on its science. This chart reflects the high valuation of this "intellectual capital."
%20of%20the%20company%20Aerovate%20Therapeutics%20(AVTE)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Aerovate-Therapeutics-AVTE&v=1772648088997 "Chart of market capitalization per employee (in thousands of dollars) of the company Aerovate Therapeutics (AVTE)")
Market capitalization per employee (in thousands of dollars) in the market segment - Heart
Aerovate Therapeutics is developing an innovative inhaled drug for the treatment of pulmonary arterial hypertension, a severe heart and lung disease. The clinical-stage company's entire market value lies in the potential of this development. This chart reflects the market's high valuation of the intellectual capital generated by a small team of scientists.
%20by%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Heart&v=1772648089026 "Market capitalization per employee (in thousands of dollars) by market segment - Heart")
Market capitalization per employee (in thousands of dollars) for the overall market
Aerovate Therapeutics is a clinical-stage biopharmaceutical company developing a drug for the treatment of pulmonary arterial hypertension. Its market capitalization is based on its scientific potential. This chart shows the typical high valuation per employee for biotech, where investors are betting on the future success of a small scientific team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772648089046 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Aerovate Therapeutics (AVTE)
Aerovate Therapeutics is a clinical-stage biotech developing an inhaled drug (AV-101) for the treatment of pulmonary arterial hypertension. This is pure R&D. This chart shows the company's capital burn rate: how much the company spends (negative profit) on each scientist to conduct expensive clinical trials.
%20Chart%20Aerovate%20Therapeutics%20(AVTE)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Aerovate-Therapeutics-AVTE&v=1772648089135 "Company Profit Per Employee (in thousands of dollars) Chart Aerovate Therapeutics (AVTE)")
Profit per employee (in thousands of dollars) in the market segment - Heart
Aerovate Therapeutics is a clinical-stage biopharmaceutical company focused on the treatment of pulmonary arterial hypertension. This chart reflects the effectiveness of R&D management. Investors monitor this metric in the context of clinical trial news, as success in these trials could lead to the development of a highly sought-after drug.
%20in%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Heart&v=1772648089195 "Chart of profit per employee (in thousands of dollars) in the market segment - Heart")
Profit per employee (in thousands of dollars) for the market as a whole
Aerovate Therapeutics (AVTE) is a biopharmaceutical company developing an inhaled drug (AV-101) for the treatment of pulmonary arterial hypertension. It is a clinical-stage R&D company with no profit. This metric is negative and reflects the "cost" of a single scientist.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772648089218 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Aerovate Therapeutics (AVTE)
Aerovate Therapeutics is a biopharmaceutical company developing a drug for the treatment of pulmonary arterial hypertension. There is no revenue at the clinical trial stage. This chart is a starting point, showing the enormous potential if their innovative drug is successful.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Aerovate-Therapeutics-AVTE&v=1772648089277 "Sales chart per company employee Aerovate Therapeutics (AVTE)")
Sales per employee in the market segment - Heart
Aerovate Therapeutics is a clinical-stage biotech company developing an inhaled drug for the treatment of pulmonary arterial hypertension. This is an R&D business. This graph reflects their clinical stage. The productivity of their research team lies in the creation and advancement of this niche drug through clinical trials.
Sales per employee for the market as a whole
Establishment Labs (ESTA) is a medical technology company producing next-generation breast implants (Motiva) focused on safety and aesthetics. They also develop 3D modeling technologies for plastic surgery. This graph shows their performance in the medtech niche. Selling high-tech implants is a high-margin business. The growth of this indicator reflects their successful market share gains.
Short shares by company, segment and market as a whole
Shares shorted by company Aerovate Therapeutics (AVTE)
Aerovate (AVTE) is a clinical-stage biotech developing a drug to treat pulmonary hypertension. This chart tracks bearish bets. A short is a direct bet on the drug's failure in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Aerovate-Therapeutics-AVTE&v=1772648089332 "Short Shares Chart for the Company Aerovate Therapeutics (AVTE)")
Shares shorted by market segment - Heart
Aerovate (AVTE) is a biotech company developing an inhaled drug for the treatment of pulmonary arterial hypertension. The chart below represents a general short position in the biotech sector, demonstrating investor skepticism about the success of risky clinical trials.
Shares shorted by the overall market
Aerovate (AVTE) is a clinical-stage biotech. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing AVTE won't be able to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Aerovate Therapeutics (AVTE)
This chart for Aerovate is a binary bet on the treatment of pulmonary hypertension. The entire company is represented by a single drug (AV-101). "Overheating" (above 70) occurs in anticipation of Phase 2/3 data. A failure in a key study or safety concerns will immediately plunge the oscillator into "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Aerovate-Therapeutics-AVTE&v=1772648089449 "RSI 14 indicator chart for the company's stock Aerovate Therapeutics (AVTE)")
RSI 14 Market Segment - Heart
Aerovate is a biotech company, a lung hunter. They focus on an inhaled drug (AV-101) for the treatment of pulmonary arterial hypertension (PAH). The Heart (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It helps us understand: is AVTE's growth due to their R&D, or is the entire biotech sector "overheated"?
RSI 14 for the overall market
Aerovate Therapeutics (AVTE) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast AVTE (Aerovate Therapeutics)
Aerovate Therapeutics is a biotech company developing an inhaled drug (AV-101) for the treatment of pulmonary arterial hypertension (PAH). This chart shows the average 12-month analyst forecast, representing their collective speculative bet on the success of clinical trials for this R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-AVTE-Aerovate-Therapeutics&v=1772648089493 "A chart showing analyst consensus forecasts for the expected stock price. AVTE (Aerovate Therapeutics)")
The difference between the consensus estimate and the actual stock price AVTE (Aerovate Therapeutics)
Aerovate (AVTE) is a biotech rocket targeting the massive pulmonary arterial hypertension (PAH) market. Their bet is on an inhaled form (AV-101) of a proven drug. This chart shows how far the current share price differs from the "fair" value. It reflects analysts' binary belief in the success of their key clinical trials.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-AVTE-Aerovate-Therapeutics&v=1772648089521 "A chart showing the difference between the consensus forecast and the actual stock price. AVTE (Aerovate Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Heart
Aerovate (AVTE) is a biotech company developing an inhaled drug (AV-101) for the treatment of pulmonary arterial hypertension (PAH). This chart shows analysts' overall expectations for the cardiology sector. It reflects whether experts believe in a breakthrough in R&D for this rare and severe disease.
Analysts' consensus forecast for the overall market share price
Aerovate Therapeutics (AVTE) is a clinical-stage biopharmaceutical company focused on treating pulmonary arterial hypertension, a rare and severe heart and lung disease. This chart shows the overall market risk appetite and serves as an indicator of the "open" or "closed" funding window for speculative biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Aerovate Therapeutics
Aerovate is a biotech R&D company with one bet: pulmonary arterial hypertension (PAH). Their signature drug (AV-101) is an inhaled (not pill) dry powder version for the treatment of this deadly disease. This chart is a pure R&D barometer. Its dynamics are all or nothing, depending entirely on their (very risky) clinical trial data.
AKIMA Market Segment Index - Heart
Aerovate Therapeutics is a biopharmaceutical company focused on the rare and severe disease pulmonary arterial hypertension. They are developing an inhaled drug to improve breathing. This chart compares their composite index to the sector, showing how their cardiopulmonary approach compares to others.
The AKIM Index for the overall market
Aerovate Therapeutics, a biotech company developing inhaled imatinib for pulmonary hypertension, suffered a failed trial. This chart, reflecting the market average, provides a macro backdrop. It helps assess how a cash-rich company seeking a new direction compares to overall trends.
